// App-Quantinova.ai

1507 : Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis

Researchers

Presenter

  • Lianne Gensler

Principal Investigators

  • Jonathan Kay

  • Walter P. Maksymowych

  • Nigil Haroon

  • Robert B.M. Landewe

  • Martin Rudwaleit

  • Stephen Hall

  • Lars Bauer

  • Bengt Hoepken

  • Natasha de Peyrecave

  • Thomas Kumke

  • Desiree van der Heijde

Medical Centers

  • Oregon Health and Science University, Portland, OR

  • University of California, San Francisco, CA

  • University of Massachusetts Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA

  • University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada

  • Toronto Western Hospital, Toronto Western Research Institute, and University of Toronto, Toronto, ON, Canada

  • VU University Medical Center, Amsterdam, Netherlands

  • Klinikum Bielefeld, Charité Berlin, Gent University, Bielefeld, Germany

  • Monash University and Emeritus Research, Melbourne, Australia

  • UCB Pharma, Monheim am Rhein, Germany

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Monheim, Germany

  • Leiden University Medical Centre, Leiden, Netherlands

Locations

  • United States

  • Canada

  • Netherlands

  • Germany

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Non-radiographic axial spondyloarthritis

  • Axial spondyloarthritis

Biomarkers

  • C reactive protein

  • Cluster of differentiation 95

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved